Brand Institute announced its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022. As a product, VEGZELMA® (bevacizumab-adcd) is the fourth bevacizumab biosimilar currently approved in the United States. VEGZELMA® is indicated for the treatment of patients with: Metastatic colorectal cancer; Recurrent or metastatic non-squamous non-small cell lung cancer; Recurrent glioblastoma; Metastatic renal cell carcinoma; Persistent, recurrent, or metastatic cervical cancer; and Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
1st Jan change | Capi. | |
---|---|---|
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |